Hourglass Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Hourglass Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,842	Closed	-$3.09M	–	135
2021 Q2	$3.09M	Hold	21,842	–	–	0.72%	49
2021 Q1	$2.18M	Hold	21,842	–	–	0.55%	52
2020 Q4	$2.7M	Hold	21,842	–	–	0.8%	47
2020 Q3	$2.13M	Hold	21,842	–	–	0.72%	49
2020 Q2	$3.41M	Hold	21,842	–	–	1.21%	37
2020 Q1	$3.15M	Hold	21,842	–	–	1.34%	36
2019 Q4	$4.46M	Sell	21,842 -5,461	-20%	-$996K	1.21%	39
2019 Q3	$2.19M	Hold	27,303	–	–	0.62%	51
2019 Q2	$2.58M	Hold	27,303	–	–	0.73%	49
2019 Q1	$2.33M	Hold	27,303	–	–	0.68%	47
2018 Q4	$1.53M	Buy	+27,303	New	+$1.67M	0.48%	53

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Hourglass Capital's RETA Position: Q3 2021 in Review

Hourglass Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 21,842 shares — an estimated $3.09M sold.

Hourglass Capital first reported a position in RETA in Q4 2018 and held it in 11 quarters. The position peaked at $4.46M in Q4 2019. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

Hourglass Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
Hourglass Capital sold 21,842 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $3.09M.
Hourglass Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 11 quarters.
Hourglass Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.46M in Q4 2019.
181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on Hourglass Capital's 13F filing for Q3 2021, filed 12 Nov 2021.